Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

Transfusion

Volumn 55, Issue 3, 2015, Pages 605-610

  Weinstock, Christof ^a   Möhle, Robert ^b   Dorn, Christiane ^b   Weisel, Katja ^b   Höchsmann, Britta ^a   Schrezenmeier, Hubert ^a   Kanz, Lothar ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; ECULIZUMAB; HEMOGLOBIN; HEPARIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; BLOOD GROUP ABO SYSTEM; C3 PROTEIN, HUMAN; COMPLEMENT COMPONENT C3; GLYCOSYLPHOSPHATIDYLINOSITOL; PREDNISOLONE;

ANEMIA; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BLOOD; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP B; BLOOD GROUP TYPING; CASE REPORT; CELL SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG USE; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; ACUTE DISEASE; ANEMIA, HEMOLYTIC; ANTAGONISTS AND INHIBITORS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; COMPLEMENT ACTIVATION; COMPLICATION; DRUG EFFECTS; ERYTHROCYTE; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; MEDICAL ERROR; TRANSFUSION REACTION; URINE;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GROUP INCOMPATIBILITY; CELL SURVIVAL; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5A; ERYTHROCYTES; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMOGLOBINURIA; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEDICAL ERRORS; PREDNISOLONE; TRANSFUSION REACTION;

EID: 84924514294     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12882     Document Type: Article

References (21)

1. Serious Hazards of Transfusion Steering Committee. Serious hazards of transfusion: annual report 2012. Manchester (UK): SHOT Office; 2013. Available from: http://www.shotuk.org/wp-content/uploads/2013/08/SHOT-Annual-Report-2012.pdf
2. Kohl J,. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38: 175-187.
3. Egawa G, Nakamizo S, Natsuaki Y, et-al. Intravital analysis of vascular permeability in mice using two-photon microscopy. Sci Rep 2013; 3: 1932.
4. Webster BH,. Clinical presentation of haemolytic transfusion reactions. Anaesth Intensive Care 1980; 8: 115-119.
5. Goldfinger D,. Acute hemolytic transfusion reactions-a fresh look at pathogenesis and considerations regarding therapy. Transfusion 1977; 17: 85-98.
6. Hillmen P, Young NS, Schubert J, et-al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
7. Legendre CM, Licht C, Muus P, et-al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181.
8. Soliris.net. U.S. prescribing information. April 2014 [cited 2014 Sep 12]. Available from: http://soliris.net/sites/default/files/assets/soliris-pi.pdf
9. Hill A, Kelly RJ, Hillmen P,. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121: 4985-4996.
10. Wagner FF, Flegel WA,. Analysis by flow cytometry of chimerism after bone marrow transplantation and of erythrocyte antigen density. In:, Gutensohn K, Sonneborn HH, Kühnl P, editors. Aspects of the flow-cytometric analysis of red blood cells. 1st ed. Heidelberg: Clin Lab Publications; 1997. p. 95-103.
11. Höchsmann B, Rojewski M, Schrezenmeier H,. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann Hematol 2011; 90: 887-899.
12. Feldschuh J, Enson Y,. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977; 56: 605-612.
13. Rother RP, Rollins SA, Mojcik CF, et-al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-1264.
14. Dacie JV, Firth D,. Blood transfusion in nocturnal haemoglobinuria. Br Med J 1943; 1: 626-628.
15. Brecher ME, Taswell HF,. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited. Transfusion 1989; 29: 681-685.
16. Klein HG, Anstee DJ,. ABO, Lewis and P groups and Ii antigens. In:, Klein HG, Anstee DJ, editors. Mollison's blood transfusion in clinical medicine. 11th ed. London: Blackwell Publishing Ltd.; 2007. p. 114-162.
17. Risitano AM, Notaro R, Pascariello C, et-al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012; 119: 6307-6316.
18. Hochsmann B, Leichtle R, von Zabern I, et-al. Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sang 2012; 102: 159-166.
19. Hillmen P, Muus P, Roth A, et-al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162: 62-73.
20. Stewart ZA, Collins TE, Schlueter AJ, et-al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012; 44: 3033-3036.
21. Biglarnia AR, Nilsson B, Nilsson T, et-al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24: e61-66.